Corporate overview

  • Home
  • Corporate overview

Company Information

  • Corporate name

    BioMimetics Sympathies Inc.

  • Date of establishment

    November 28, 2000

  • List of officers

    Naoki Urushihata , Chief Executive Officer
    Keisuke Onishi , Chief Technical Officer
    Calvin Chen , Chief Operating Officer
    Tetsuo Koike , Director
    Kazuharu Tomioka , Director
    Shigeo Jokura, Auditors
    Takashi Sueki , Auditors(Tax accountant)
    Yoshiaki Ohba , Auditors (Certified administrative procedures legal specialist)

  • Capital stock

    2,033,300,000 yen (as of March 2023)

  • Number of employees

    18 (as of March 2023)

  • Business

    ・Research development and clinical development related to cellular medicinal products
    ・Licensing out of products, intellectual properties, and rights related to regenerative medicine
    ・Cosmetics, reagents and culture medium business based on regenerative medicine technology
    ・Development of regenerative medicine-related businesses
    ・Regenerative medicine support

  • Address

    TIME 24 Building 19F, 2-4-32 Aomi, Koto-ku, Tokyo 135-0064, Japan

    Access
  • Telephone number

    03-5500-6330

  • FAX

    03-5500-6336

  • Legal advisors

    Fairness Law Office
    Uchida & Samejima Law Firm
    Kurahashi Law Firm

Corporate history

2000 Started joint research with domestic and overseas research institutes such as Keio University and Monell Chemical Senses Center in the United States for early detection of cancer using dog to detect cancer from body odor and exhaled breath, and after conducting many studies, the technology was transferred. Later on focused on specializing in regenerative medicine.
2007 The regenerative medicine business entered.
Development of an animal oringin-free culture technology for mesenchymal stem cells started at full scale.
2008 Consulting on the design and management of CPCs started to be provided to medical institutions.
2011 Technology for culturing high-quality mesenchymal stem cells completed.
The office relocated to the Odaiba area, Tokyo (current office).
A large-scale CPC constructed and started to be managed in the Odaiba area, Tokyo.
Culture contract business targeted at medical institutions providing regenerative medicine started.
2013 A joint research on regenerative medicine with ROHTO Pharmaceutical Co., Ltd. started.
https://www.rohto.co.jp/news/release/2013/0514_01/
2014 The corporate renamed BioMimetics Sympathies Inc.
2015 Licensed as a cell-processing center.
Culture contract business started under the Act on the Safety of Regenerative Medicine.
An academic-industry collaboration program kicked off at Tokyo Medical University (until March 2018)
2016 Sales of cosmetic ingredients started.
2019 Sales business of culture medium expanded.
2020 Sales of in-house cosmetics started.
2021 Discovered candidate substances for treatment of COVID-19 infections (patented) and succeeded in license out to a pharmaceutical company.
2022 Selected for AMED public offering "FY2022 Research Program on Emerging and Re-emerging Infectious Diseases"
Established a joint ventures with China's global biotechnology company Bloomage Biotechnology Co., Ltd. (Head office: Haikou, Hainan) and multiple companies including ROHTO Pharmaceutical Co., Ltd., on Hainan Island, China.

Contact

For consultations with and inquiries regarding BioMimetics Sympathies Inc, please feel free to contact us from the designated page.

Contact